Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. News related to Oragenics often centers on the progress of its lead intranasal drug candidate, ONP-002, which is being advanced for the treatment of concussion and mild traumatic brain injury, as well as broader developments in its intranasal platform for neurological disorders.
Investors and followers of OGEN can use this news feed to track company announcements about clinical milestones, such as Human Research Ethics Committee approval in Australia, selection of Southern Star Research as Clinical Research Organization for the Phase IIa ONP-002 trial, and updates on anticipated Phase IIa and Phase IIb studies. Oragenics’ press releases also cover manufacturing and operational agreements, including its cGMP production partnership with Sterling Pharma Solutions to supply ONP-002 for clinical development.
Another recurring theme in Oragenics news is strategic and financial activity. The company has reported public offerings of Series H Convertible Preferred Stock and Warrants, at-the-market equity sales, and related steps taken to restore and maintain compliance with NYSE American stockholders’ equity requirements. These updates provide context on how Oragenics is funding its clinical programs and strengthening its balance sheet.
In addition, Oragenics issues news about pipeline expansion and partnerships, including its collaboration with Receptor.AI, an artificial intelligence–driven drug profiling company, aimed at accelerating development of additional pharmaceutical candidates for brain health. The company also announces its participation in industry conferences and investor events, where it presents its intranasal concussion program and broader neurological platform. Readers interested in OGEN can follow this page for ongoing disclosures directly sourced from company press releases and related regulatory communications.
Oragenics, Inc. (NYSE American: OGEN) announced that it has regained compliance with NYSE American’s continued listing standards as of
Oragenics, Inc. (NYSE American: OGEN) announced a 1-for-60 reverse stock split approved by its Board on
Oragenics, Inc. (NYSE American: OGEN) announced findings from its GLP toxicology study of the NT-CoV2-1 intranasal vaccine candidate, reporting no toxicity signals or adverse events. The study supports the company's plan to file for regulatory approval for a Phase 1 clinical study. With no toxicity observed, the vaccine demonstrates a favorable safety and immunogenicity profile. Oragenics aims to address the unmet need for intranasal COVID-19 vaccines, with positive preclinical data indicating strong immune responses against various SARS-CoV-2 variants.
Oragenics, Inc. (AMEX:OGEN) has received a compliance notice from NYSE American, indicating that its stock price has been low for an extended period. The company must improve its stock price or undertake a reverse stock split by June 19, 2023, to regain compliance. The notice does not lead to immediate delisting and stocks will continue trading with a designation of 'BC'. Oragenics remains dedicated to developing its intranasal COVID-19 vaccine and lantibiotics, although the notice may impact future financing efforts.
On December 16, 2022, Oragenics, Inc. (AMEX: OGEN) announced the appointment of Charles Pope as Chairman of the Board, succeeding Dr. Frederick W. Telling. Dr. Telling will remain on the Board as an independent director. Mr. Pope expressed gratitude for Dr. Telling's long service and looks forward to continuing the company's advancement in developing its product candidates, including an intranasal vaccine for COVID-19. Oragenics focuses on combating infectious diseases and is working on new antibiotic solutions.
Oragenics, Inc. (NYSE American: OGEN) is participating in the 2022 BioFlorida Annual Conference from November 2-4 in Miami. The company's President and CEO, Kim Murphy, will speak on a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on November 3 at 2:05 p.m. Eastern Time, held at the Hyatt Regency Miami. Murphy will also engage in one-on-one meetings with investors. Oragenics is focused on developing therapies for infectious diseases, including an intranasal COVID-19 vaccine candidate.
Oragenics, Inc. (NYSE American: OGEN) announced its plans for NT-CoV2-1, an intranasal COVID-19 vaccine, which aims to enhance mucosal immunity. The company is progressing into human clinical trials in early 2023 after favorable results from preclinical studies, including a pivotal toxicology study expected to conclude this year. With advantages like easier administration and greater storage efficiency, Oragenics anticipates NT-CoV2-1 will be pivotal in combating COVID-19 variants. The company plans to submit a Clinical Trial Application to Health Canada following the toxicology report.
Oragenics, Inc. (NYSE American: OGEN) announced preliminary positive results from a GLP toxicology study for its NT-CoV2-1 intranasal COVID-19 vaccine candidate. The data indicates a favorable safety profile and immune response, supporting regulatory filings for a Phase 1 clinical study expected to start by early 2023. Notably, the vaccine candidate has shown strong preclinical immune responses against various SARS-CoV-2 variants, highlighting its potential as a needle-free option to reduce COVID-19 transmission.
Oragenics, Inc. (NYSE American: OGEN) has appointed Kimberly M. Murphy as President and CEO effective June 23, 2022. Murphy, a seasoned vaccine industry leader with over 25 years of experience, has previously held significant roles at companies like Merck and GSK. Her appointment is expected to enhance Oragenics' strategic vision and accelerate growth, particularly in their ongoing vaccine development efforts against infectious diseases, including COVID-19. As a board member since 2020, her insights have already contributed to the company’s strategies.
Oragenics (AMEX:OGEN), a biotech firm, announced the publication of a study on its intranasal COVID-19 vaccine candidate, NT-CoV2-1, in Scientific Reports. Co-authored with Inspirevax and the National Research Council of Canada, the study demonstrated efficacy in mice and hamsters, highlighting robust immune responses. The company aims to use this data, alongside ongoing toxicology studies, to support its application for human clinical trials. Oragenics focuses on developing treatments for infectious diseases, emphasizing innovative vaccine delivery methods.
FAQ
What is the current stock price of Oragenics (OGEN)?
What is the market cap of Oragenics (OGEN)?
